TBPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Theravance Biopharma Inc (TBPH) is not a strong buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The technical indicators suggest a bearish trend, options data reflects negative sentiment, and insider selling is significant. Additionally, the company's financial performance shows declining net income and EPS despite revenue growth. Without strong positive catalysts or favorable trading signals, holding off on buying is recommended.
The MACD is negative and expanding downward (-0.138), indicating bearish momentum. RSI is at 24.587, suggesting the stock is nearing oversold territory but not providing a clear signal. Moving averages are converging, showing no strong directional trend. Key support is at $18.247, with resistance at $19.176. Current pre-market price is $18.18, close to support levels.
Gross margin remains at 100%, indicating operational efficiency.
Insiders are selling heavily, with a 411.55% increase in selling activity over the last month. Net income dropped by -128.47% YoY, and EPS declined by -126.92% YoY. The MACD and options data suggest bearish sentiment. No recent congress trading data or influential figure activity to support a positive outlook.
In Q3 2025, revenue grew by 18.51% YoY to $19.99M. However, net income dropped significantly by -128.47% YoY to $3.615M, and EPS fell by -126.92% YoY to $0.07. Gross margin remained stable at 100%. Overall, financial performance shows revenue growth but declining profitability.
No data available for trend analysis or recent analyst ratings. Wall Street sentiment is unclear.
